Condensed Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands		Total	Preferred stock	Common stock	Additional paid-in capital	Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2022			0
Balance, beginning of period at Dec. 31, 2022		$ (176,329)	$ 0	$ 0	$ 10,028	$ (186,358)
Balances, beginning of period (in shares) at Dec. 31, 2022				347,926
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of options (in shares)		95,842
Exercise of options		$ 50			50
Stock-based compensation		73			73
Deemed dividend		0			959	(959)
Net loss		(8,313)				(8,313)
Ending balance (in shares) at Mar. 31, 2023			0
Balance, end of period at Mar. 31, 2023		(184,519)	$ 0	$ 0	11,110	(195,630)
Balances, end of period (in shares) at Mar. 31, 2023				443,769
Beginning balance (in shares) at Dec. 31, 2022			0
Balance, beginning of period at Dec. 31, 2022		(176,329)	$ 0	$ 0	10,028	(186,358)
Balances, beginning of period (in shares) at Dec. 31, 2022				347,926
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(23,724)
Ending balance (in shares) at Sep. 30, 2023			4,015,002
Balance, end of period at Sep. 30, 2023		8,292	$ 1	$ 2	221,351	(213,062)
Balances, end of period (in shares) at Sep. 30, 2023				26,316,682
Beginning balance (in shares) at Mar. 31, 2023			0
Balance, beginning of period at Mar. 31, 2023		(184,519)	$ 0	$ 0	11,110	(195,630)
Balances, beginning of period (in shares) at Mar. 31, 2023				443,769
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of options (in shares)				4,592
Exercise of options		16			16
Stock-based compensation		69			69
Deemed dividend		0			2,022	(2,022)
Net loss		(13,985)				(13,985)
Ending balance (in shares) at Jun. 30, 2023			0
Balance, end of period at Jun. 30, 2023		(198,419)	$ 0	$ 0	13,217	(211,637)
Balances, end of period (in shares) at Jun. 30, 2023				448,361
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of options (in shares)				50,646
Exercise of options		29			29
Stock-based compensation		259			259
Issuance of common stock (in shares)				21,500,867
Conversion of redeemable convertible preferred stock into common stock in connection with the Business Combination		204,236		$ 2	204,234
Assumption of warrants to purchase common stock in connection with the Business Combination		(2,568)			(2,568)
Issuance of common stock upon closing the Business Combination, net of expenses (in shares)				4,316,808
Issuance of common stock upon closing the Business Combination, net of expenses		957			957
Contingent earnout liability recognized upon closing of the Business Combination		(28,927)			(28,927)
Proceeds from sale of common stock (in shares)			4,015,002
Proceeds from sale of common stock		34,151	$ 1		34,150
Net loss		(1,425)				(1,425)
Ending balance (in shares) at Sep. 30, 2023			4,015,002
Balance, end of period at Sep. 30, 2023		$ 8,292	$ 1	$ 2	221,351	(213,062)
Balances, end of period (in shares) at Sep. 30, 2023				26,316,682
Beginning balance (in shares) at Dec. 31, 2023		4,015,002	4,015,002
Balance, beginning of period at Dec. 31, 2023		$ (27,065)	$ 0	$ 2	222,437	(249,504)
Balances, beginning of period (in shares) at Dec. 31, 2023		26,413,213		26,413,213
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of options (in shares)	[1]			(4,941)
Exercise of options (in shares)				2,906
Exercise of options		$ 7			7
Stock-based compensation		1,086			1,086
Proceeds from sale of common stock (in shares)				350,000
Proceeds from sale of common stock		3,141			3,141
Net loss		(13,206)				(13,206)
Ending balance (in shares) at Mar. 31, 2024			4,015,002
Balance, end of period at Mar. 31, 2024		$ (36,037)	$ 0	$ 2	226,671	(262,710)
Balances, end of period (in shares) at Mar. 31, 2024				26,758,272
Beginning balance (in shares) at Dec. 31, 2023		4,015,002	4,015,002
Balance, beginning of period at Dec. 31, 2023		$ (27,065)	$ 0	$ 2	222,437	(249,504)
Balances, beginning of period (in shares) at Dec. 31, 2023		26,413,213		26,413,213
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of options (in shares)		1,178
Net loss		$ (19,937)
Ending balance (in shares) at Sep. 30, 2024		3,985,002	3,985,002
Balance, end of period at Sep. 30, 2024		$ (20,434)	$ 0	$ 3	249,004	(269,441)
Balances, end of period (in shares) at Sep. 30, 2024		30,469,664		30,469,664
Beginning balance (in shares) at Mar. 31, 2024			4,015,002
Balance, beginning of period at Mar. 31, 2024		$ (36,037)	$ 0	$ 2	226,671	(262,710)
Balances, beginning of period (in shares) at Mar. 31, 2024				26,758,272
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of options (in shares)				1,191
Exercise of options		5			5
Stock-based compensation		1,275			1,275
Proceeds from sale of common stock (in shares)				400,000
Proceeds from sale of common stock		3,602			3,602
Record exchange warrants		11,923			11,923
Record issuance costs		(1,699)			(1,699)
Net loss		(4,332)				(4,332)
Ending balance (in shares) at Jun. 30, 2024			4,015,002
Balance, end of period at Jun. 30, 2024		(25,263)	$ 0	$ 2	241,777	(267,042)
Balances, end of period (in shares) at Jun. 30, 2024				27,159,463
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of options (in shares)				660
Exercise of options		2			2
Stock-based compensation		1,383			1,383
Issuance of common stock (in shares)				2,110,366
Proceeds from sale of common stock (in shares)				1,166,530
Proceeds from sale of common stock		5,843		$ 1	5,842
Preferred stock conversion (in shares)			(30,000)	32,645
Net loss		$ (2,399)				(2,399)
Ending balance (in shares) at Sep. 30, 2024		3,985,002	3,985,002
Balance, end of period at Sep. 30, 2024		$ (20,434)	$ 0	$ 3	$ 249,004	$ (269,441)
Balances, end of period (in shares) at Sep. 30, 2024		30,469,664		30,469,664

[1] Amount reflects 2,906 shares issued for option exercises and 7,847 shares returned from options exercised in 2023 to correct clerical error.